HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Schering Plans For Possible Clarinex Switch By Readying OTC Division

This article was originally published in The Tan Sheet

Executive Summary

Preparations for a possible Rx-to-OTC switch of Clarinex (desloratadine) will be directed by Schering Consumer Health Care Division Chairman Stanley Barshay

You may also be interested in...



Claritin Hives Relief Approval Could Close Out Rx Product Line

Schering-Plough will not be granted marketing exclusivity for its OTC Claritin Hives Relief,following FDA approval Nov. 19

Schering Cost Cuts Run Deep: Consumer Health Unit In Danger Of Divestiture?

Schering-Plough will retain its Consumer Health Care business in the near-term but may choose to sell the unit as it undertakes a broad restructuring plan that includes an unprecedented dividend slash to cut costs

Schering Taps Former AHP Exec Barshay To Head Consumer Health Care Unit

Schering-Plough appointed former American Home Products Senior VP Stanley Barshay as chairman of its Consumer Health Care division effective July 7

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS129476

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel